Proton Beam Therapy for Chordoma Patients
Learn more about:
Related Clinical Trial
Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas
Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma
Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma
Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine
Proton Therapy for Chordomas and/or Chondrosarcomas
Afatinib in Locally Advanced and Metastatic Chordoma
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base
Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas
BN Brachyury and Radiation in Chordoma
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
Pemetrexed for the Treatment of Chordoma
Proton Radiation for Chordomas and Chondrosarcomas
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
Proton Beam Therapy for Chordoma Patients
Efficacy and Safety of Imatinib in Chordoma
Nilotinib With Radiation for High Risk Chordoma
Chordoma Family Study
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma
Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families